Protagenic Therapeutics Statistics
Total Valuation
PTIX has a market cap or net worth of $2.90 million. The enterprise value is $1.85 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PTIX has 4.47 million shares outstanding. The number of shares has increased by 2.87% in one year.
| Current Share Class | 4.47M |
| Shares Outstanding | 4.47M |
| Shares Change (YoY) | +2.87% |
| Shares Change (QoQ) | +1.93% |
| Owned by Insiders (%) | 21.77% |
| Owned by Institutions (%) | 3.70% |
| Float | 3.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.34 |
| P/TBV Ratio | 4.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.80
| Current Ratio | 1.80 |
| Quick Ratio | 1.34 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -410.05 |
Financial Efficiency
Return on equity (ROE) is -231.87% and return on invested capital (ROIC) is -124.50%.
| Return on Equity (ROE) | -231.87% |
| Return on Assets (ROA) | -94.91% |
| Return on Capital (ROIC) | -124.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.88M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.75% in the last 52 weeks. The beta is 0.25, so PTIX's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -18.75% |
| 50-Day Moving Average | 0.62 |
| 200-Day Moving Average | 0.96 |
| Relative Strength Index (RSI) | 51.67 |
| Average Volume (20 Days) | 241,323 |
Short Selling Information
The latest short interest is 89,119, so 1.99% of the outstanding shares have been sold short.
| Short Interest | 89,119 |
| Short Previous Month | 125,616 |
| Short % of Shares Out | 1.99% |
| Short % of Float | 2.74% |
| Short Ratio (days to cover) | 1.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.27M |
| Pretax Income | -6.01M |
| Net Income | -5.65M |
| EBITDA | -5.21M |
| EBIT | -5.27M |
| Earnings Per Share (EPS) | -$1.27 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 1.06M |
| Total Debt | n/a |
| Net Cash | 1.06M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 719,007 |
| Book Value Per Share | 0.15 |
| Working Capital | 633,389 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.54 million and capital expenditures -$93,969, giving a free cash flow of -$4.64 million.
| Operating Cash Flow | -4.54M |
| Capital Expenditures | -93,969 |
| Free Cash Flow | -4.64M |
| FCF Per Share | -$1.04 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |